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Abstract: Ocular Surface Disease (OSD) is prevalent among medically treated patients with glaucoma. This is basically 
related to three key-points: OSD and glaucoma are both prevalent in elderly and are common comorbidities in the same 
patient; the role of the active ingredient of the medical antiglaucomatous therapy; the role of the preservative agent of this 
medical therapy. 
Considering the actual state of literature we can state that the active glaucoma agent have a role in OSD, but the main 
cause seems to be the preservative agent, in particular referring to benzalkonium chloride, BAK. 
In the clinical evaluation of dry eye patients there is no actually established gold standard. Since the ocular surface injury 
not only causes dry eye, red eye, eye itching, photophobia and other discomforts, but also increases the risk of failure of 
glaucoma surgery in patients, it becomes fundamental a complete and good clinical evaluation of OSD (considering 
Schirmer’s test, tear breakup time, corneal and conjunctival staining) together with a good evaluation of patients’ quality 
of life (with validated questionnaires). 
Development of complex preparations, preservative-free and/or novel preservative preparations for glaucoma therapy 
could provide a promising approach in the prevention of ocular surface injuries. 
Keywords: Benzalkonium chloride (BAK), dry eye, glaucoma, ocular surface disease (OSD), quality of life (QoL). 
INTRODUCTION 
 Primary open angle glaucoma (POAG) is a progressive 
neurodegeneration of retinal ganglion cells (RCGs) and their 
axons characterized by a specific pattern of visual field and 
optic nerve head damage [1, 2]. Clinical trials confirmed the 
importance of intraocular pressure (IOP) in the development 
and progression of open-angle glaucoma, even if evidence 
suggests the existence of ocular and systemic factors, in 
addition to IOP, that can be responsible of this development 
and progression. IOP is still the only risk factor that we can 
effectively treat with medical and surgical therapy [3, 4]. 
 Tear film deficiencies are among the most common eye 
problems [5] : epidemiologic studies have reported that more 
than 6% of the population over the age of 40 suffer from dry 
eye, with the prevalence increasing to 15% of the population 
over the age of 65 [6-8]. Using a prevalence of 6% and the 
2000 census data, there are an estimated 7.1 million people 
in the US over the age of 40 who experience dry eye 
symptoms. Most studies have found an increasing prevalence 
with age and some studies have shown a greater prevalence 
of dry eye among women [9-11]. 
 The 2007 International Dry Eye WorkShop (DEWS) 
defined dry eye as a multifactorial disorder of the tear film 
and ocular surface that results in eye discomfort, visual  
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disturbance, and often ocular surface damage, characterized 
by hyperosmolarity of tear film and inflammation of ocular 
surface [12]. 
 Dry Eye Disease (DED) - associated to Ocular Surface 
Disease (OSD) - can be described as a disorder involving 
multiple interacting mechanisms [12, 13]. Dysfunction of 
any lacrima function unit component can lead to DED by 
causing alterations in the volume, composition, distribution, 
and/or clearance of the tear film. Two mutually reinforcing 
mechanisms, tear hyperosmolarity and tear film instability, 
have been identified [12]. Tear hyperosmolarity can arise 
from both low aqueous flow or excessive evaporation. 
Hyperosmolar tears can damage ocular surface epithelium by 
activating an inflammatory cascade. While acute inflammat-
ion may initially be accompanied by increased reflex tearing 
and blinking, chronic inflammation may result in reduced 
corneal sensation and decreased reflex activity, leading to 
increased evaporation and tear film instability. Inflammation 
can also result in goblet cell loss and decreased mucin 
production, which further contributes to tear film instability. 
Tear film instability can arise secondary to hyperosmolarity, 
or can be the initiating event, as in lipid layer abnormalities 
following meibomian gland disease. Tear film instability 
results in increased evaporation, which contributes to tear 
hyperosmolarity. Regardless of the initiating event or 
etiology, inflammation is usually a key factor in perpetuating 
DED [14]. Chronic DED may result in further pathologic 
changes. For example, patients with moderate to severe DED 
may develop reversible squamous metaplasia and punctate 
erosions of the ocular surface epithelium [15]. DED is also 
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the most common cause of filamentary keratitis, a condition 
characterized by strands of degenerated epithelial cells and 
mucus attached to the cornea. Friction between the filaments 
and the eyelid during blinking can result in further epithelial 
damage, inflammation, and filament formation. Filamentary 
keratitis often becomes chronic, and is a common finding in 
severe DED [16, 17]. Rarely, severe DED may lead to 
complications such as ocular surface keratinization, 
microbial keratitis, corneal neovascularization, ulceration, 
perforation, and scarring and finally severe vision loss [18]. 
DISCUSSION 
 Ocular Surface Disease and DED are prevalent 
among medically treated patients with glaucoma. Patients 
with glaucoma and ocular hypertension suffer OSD at a 
higher prevalence rate than patients without these ocular 
conditions [19]. 
 This is related basically to three concepts: 
1. OSD and glaucoma are both prevalent in elderly and 
are common comorbidities in the same patient [20]. 
OSD has an age-dependent prevalence, affecting 
approximately 11% of patients between the ages of 40 
and 59 and 18% of those older than age 80 [21]. The 
prevalence of POAG also increases with age.The 
glaucoma risk increasing with the age was noticed in 
almost all population studies [4]. Tsai [22] concluded 
that 66% of subjects with severe OSD also have 
glaucoma. 
2. The role of the active ingredient of the medical 
therapy. 
3. The role of the preservative agent (particularly 
benzalkonium chloride, BAK) of the medical therapy. 
 We already explained the close relationship between age 
and both POAG and OSD. It is mandatory to better explain 
the role of the glaucoma therapy. 
The Role of the Active Ingredient of the Medical Therapy 
 The benefit of IOP reduction in the treatment of glau-
coma has been confirmed in large controlled, prospective 
clinical trials. Medical treatment is predominantly used as 
first line therapy and therefore the majority of patients 
receive several decades of treatment. The main topical 
hypotensive medications include timolol (non-selective 
adrenergic beta-blocker), carteolol (non-selective adrenergic 
beta-blocker with intrinsic sympathomimetic activity), 
carbonic anhydrase inhibitors as dorzolamide or brinzol-
amide, brimonidine (adrenergic agonist alpha-2 selective), 
prostaglandin analogues (latanoprost, travoprost, bimato-
prost, tafluprost). Prostaglandin analogues and beta-blockers 
are the most commonly prescribed first-line therapies [1, 2]. 
Timolol, introduced in 1978, in a few years [23] became the 
most widely used drug in the treatment of glaucoma since it 
was approved for general use. Despite the major 
contraindications (asthma, history of obstructive pulmonary 
disease, sinus bradycardia, heart block or cardiac failure) 
today it is one of the most used drugs and is also available in 
fixed-dose combinations. Already in 1979 Nielsen and 
Eriksen [24] underlined how in 64 patients treated with 
timolol eye drops, seven patients developed transitory 
sensation of dry eyes. Two of these subjects also had 
xerostomia. In all these seven patients a reduction of 
Schirmer test and break-up time was noted. Fasina et al. [25] 
evaluated the effect of Timolol maleate on tear film break-up 
time in a Nigerian population. 192 eyes of 96 subjects were 
examined in a hospital based case-control study after being 
administered pre-coded questionnaires.There was significant 
difference in the mean break-up time of cases (10.45 secs) 
and controls (30.18 secs). 
 Preservative-free timolol solution has a favourable effect 
on the tear turnover of patients with glaucoma and ocular 
hypertension in comparison with timolol containing BAK 
[26], even if the integrity of the precorneal tear film persisted 
to be affected when using timolol without BAK [26, 27]. 
Timolol without preservative can be recommended in those 
patients who have keratoconjunctivitis sicca or a borderline 
tear production in order not to increase the severity of the 
dry eye. 
 In 1996 Latanoprost, the first prostaglandin agent, was 
introduced in medical therapy, followed by Travoprost and 
Bimatoprost in 2001 and Tafluprost in 2008. Unoprostone 
was introduced in some countries in 2000. Prostaglandins 
and their combination drugs have become the top-line 
choices for treatment in the past decade because of the once-
daily dosing and great efficacy in lowering IOP. Different 
papers in literature demonstrates how switching the therapy 
from a preserved to a preservative-free prostaglandin 
preparation in topical glaucoma medication can lead to a 
great improve of OSD. 
 Generally there is no sufficient evidence to demonstrate 
that the active glaucoma agent can lead to OSD. Blondin et 
al. [28] demonstrated that carteolol, timolol, betaxolol or 
latanoprost did not activate complement system, an early 
mediator of the inflammatory response. Furthermore timolol 
and betaxolol exerted an anti-inflammatory effect by 
preventing complement activation. 
 Pisella et al. [29] even suggested a potential protective 
effect of the prostaglandin analogue and, to a lesser extent, 
timolol against the toxicity of BAK in conjunctival cells. A 
recent multicenter, international, non-interventional study 
enrolled 448 patients with glaucoma or ocular hypertension 
in therapy with one ore more topical IOP-lowering 
medications (on average 1.9 IOP-lowering medications). 
OSD was highly prevalent in the population studied. The 
worsening of OSD symptoms and score (measured with 
Ocular Surface Disease Index, OSDI) was significantly 
related to longer duration since diagnosis and higher number 
of medications [30]. Valente et al. [31] published a recent 
study to evaluate the presence of symptoms of tear film 
dysfunction by using the Ocular Surface Disease Index 
(OSDI) questionnaire in fifty glaucomatous patients and to 
examine whether they have ocular surface signs. Fifty-two 
percent of patients in therapy with preserved 
antiglaucomatous drops showed symptoms of tear film 
dysfunction. Signs of ocular surface diseases seemed to be 
greater in patients under > 2 medications. Symptoms 
correlated to signs only in patients in monotherapy with β-
blockers drops. Considering the actual state of literature we 
can conclude that the active glaucoma agent can have a role 
in OSD, but the main cause seems to be the preservative 
agent [19]. 
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The Role of the Preservative Agent of the Medical 
Therapy 
 The need for sterility in multidose eyedrops has led to the 
inclusion of an antimicrobial preservative in these solutions. 
Commonly actually used preservatives in antiglaucomatous 
therapy are BAK, Purite® (Allergan Inc., Irvine, California, 
USA), Polyquaternum 1 as Polyquad® (Alcon Research, Fort 
Worth, Texas, USA), SofZia® (Novartis AG, Basel, 
Switzerland). 
 Other preservatives include organo-mercurial derivatives 
(such as thimerosal) that precipitate bacterial proteins and 
are active against Gram-positive bacteria and non-
sporulating organisms; amidines (such as chlorhexidine) that 
damage the cytoplasmatic membrane and are active 
particularly on Gram-positive bacteria and cocci; alcohols 
(such as chlorobutanol) that can cross the bacterial lipid layer 
(bacteriostatic and antimicotic activity); parabens (the ester 
of parahydroxybenzoic acid) that target fungi and finally the 
oxychlorinated complexes which disrupt cells function. 
 The most frequently used preservative, benzalkonium 
chloride (BAK), has consistently demonstrated its toxic 
effects in laboratory, experimental, and clinical studies. As a 
quaternary ammoniums act mainly with a detergent activity, 
which dissolve bacterial walls and membranes and damage 
the cytoplasmatic contents. Nenciu et al. [32] carried out a 
40 week, prospective, randomized trial enrolling 18 patients 
divided in four groups according to their therapy: beta-
blockers, prostaglandin analogues, carbonic anhydrase 
inhibitors. The morphometric analysis of histological 
sections of conjunctiva revealed squamous metaplasia, 
inflammation and fibrosis. Also the immunohistochemistry 
confirmed the tendency to chronic inflammations. These 
findings pointed to BAK as a major causal factor of 
conjunctival metaplasia. The group of Baudouin confirmed 
histopathologic effects of antiglaucomatous drugs on the 
conjunctiva and showed similar effects in the trabecular 
meshwork with human and animal studies [33]. This 
experimental studies showed that BAK is for a large part 
responsible for these toxic or immunoinflammatory effects 
on the ocular structures. As a quaternary ammonium BAK 
has been shown to cause tear film instability, loss of goblet 
cells, conjunctival squamous metaplasia and apoptosis, 
disruption of the corneal epithelium barrier, and damage to 
deeper ocular tissues. The mechanisms causing these effects 
have not been fully elucidated, although the involvement of 
immunoinflammatory reactions with the release of 
proinflammatory cytokines, apoptosis, oxidative stress, as 
well as direct interactions with the lipid components of the 
tear film and cell membranes have been well established 
[34]. Lot of researches have been conducted to discover and 
develop less toxic preservative than BAK and quaternary 
ammoniums, but only a few have been proposed and are 
commercially available, since a preservative must be a potent 
antimicrobial agent while not being cytotoxic [34]. 
 Noecker et al. [35] investigated in rabbit eyes the effect 
of Purite®, a stabilized oxychloro complex. Although the 
adverse effects of glaucoma medications on the ocular 
surface are likely multifactorial, 1-month treatment with 
glaucoma medications containing higher levels of 
benzalkonium chloride (BAK) resulted in greater corneal 
damage and conjunctival cell infiltration than medications 
preserved with Purite ® or with lower levels of BAK. 
 Polyquad® is a polyquaternum, a family of polycationic 
polymers that are used in personal care industries. 
Polyquaternum 1 (as Polyquad®, PQ) is commonly used in 
ophthalmology. Liang H et al. [36] evaluated in rabbits a 
new formulation of travoprost 0.004% ophthalmic solution 
preserved with PQ, with commercially available 
formulations of BAK-preserved travoprost 0.004% 
ophthalmic solution and BAK-preserved latanoprost 0.005% 
ophthalmic solution, suggesting a greater safety advantage 
for the ocular surface of patients receiving chronic glaucoma 
treatment with PQ-preserved drugs. Considering Labbé et al. 
[37] PQ, except in high concentration of 0.5%, did not create 
important changes in ocular surface compared to saline 
solution, whereas BAK induced major toxic effects at mild 
to high concentrations with destruction of globet cells. 
 SofZia® is a new preservative generation that functions 
as a microbicidal agent through oxidative properties. This 
ionic buffer solution, comprised of borate, propylene glycol, 
sorbitol, and zinc chloride, converts to nontoxic byproducts 
after contact with ocular surface cations [38]. A prospective 
randomized multicentre single-masked comparative study 
[39] enrolled 220 patients with open-angle glaucoma or 
ocular hypertension who had been treated with BAK-
preserved latanoprost 0.005% monotherapy for at least 3 
months. After a switch to SofZia-preserved travoprost 
0.004% the study indicated that frequency of 
keratoconjunctival epitheliopathy significantly decreased in 
the travoprost SofZia-preserved group (p = 0.036) and the 
intergroup difference was also significant (p = 0.001). SPK 
scores and TBUT were significantly improved in the 
travoprost group (p = 0.034, 0.049), also with significant 
intergroup differences in the cornea excluding the inferior 
area and TBUT. There were no significant intergroup 
differences in changes of the hyperaemia scores and the IOP 
reduction. 
 Ammar [40] investigated the potential cytotoxicity of 
various topical ophthalmic glaucoma formulations 
containing different preservatives in cultured human 
trabecular meshwork (TM) and non-pigmented ciliary 
epithelial (NPCE) cell lines. They demonstrated that 
substitution of BAK from topical ophthalmic drugs 
(compared to SofZia® and Polyquad®) results in greater 
viability of cultured TM cells, the cells involved in the 
conventional outflow pathway. Cultured NPCE, responsible 
for aqueous inflow, appear more resilient to BAK. Anyway 
BAK enhances all characteristics of TM degeneration typical 
of glaucoma, i.e. trabecular apoptosis, oxidative stress, 
induction of inflammatory chemokines. This causes 
degeneration in acute experimental conditions, potentially 
mimicking long-term accumulation. BAK was also shown to 
access the TM after repeated instillations. These findings 
support the hypothesis that preservatives may cause further 
long-term trabecular degeneration and therefore enhance 
outflow resistance, reducing the impact of IOP-lowering 
agents [41]. 
 We can conclude that BAK is the most commonly used 
preservative in ophthalmology and is more toxic than other 
or newer preservatives [42]. Substitution of BAK with 
Polyquad®, Purite® or sofZia® resulted in significantly higher 
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percentages of live conjunctival and corneal cells. Further 
studies are needed to understand the role upon TM cells and 
the clinical implications of these findings [43]. 
 Totally preservative-free topical medication can be 
suggested for patients with ocular surface disease, frequent 
eye drop administration, proven allergy to preservatives and 
contact lens wear [43]. Improvements in OSD and quality of 
life have been demonstrated in several studies switching to 
preservative free drugs, i.e. timolol, prostaglandin agents, 
timolol/dorzolamide fixed combination, prostaglandin/ 
timolol fixed combination [44-48]. 
 We also have to underline that there is a large evidence 
from clinical and experimental studies that long-term use of 
topical drugs may induce, as a consequence of chronic ocular 
surface changes, the potential risk of failure for further 
glaucoma surgery. Subclinical inflammation has also been 
widely described in patients receiving antiglaucoma 
treatments for long periods of time, with inflammatory cell 
infiltration and fibroblast activation in the conjunctiva and 
subconjunctival space. The preservative, especially BAK, 
could induce or enhance such inflammatory changes. 
Postoperatively, the ocular surface also plays an important 
role, as the conjunctiva interacts with aqueous humor and 
subconjunctival fibrosis may block aqueous outflow and 
cause surgical failure [49]. 
 Martone et al. [50] ruled an in vivo confocal microscopy 
analysis of effects of topical antiglaucoma therapy with 
preservative on corneal innervation and morphology. The 
density of superficial epithelial cells was reduced in all 
glaucomatous patients, except for the preservative-free 
group. On the contrary, the density of basal epithelial cells of 
glaucomatous preservative therapy groups was higher than 
control and preservative-free groups. Stromal keratocyte 
activation and the number of beads were higher in all 
glaucoma preservative groups. The number of sub-basal 
nerves was lower in all glaucoma groups than in the control 
group and tortuosity was significantly higher in glaucoma 
than control groups. Confocal microscopy can be an 
important diagnostic tool in the evaluation of dry eye 
disease, with possible therapeutical implications [51, 52] as 
switching topical therapy. 
Clinical Practice 
 In clinical practice the ideal medical therapy for 
glaucoma to prevent OSD (and to improve adherence) 
follows some basic statements. 
1. The introduction of BAK-free or even preservative 
free agents in common use is a great advancement in 
glaucoma therapy, considering that this therapy is a 
continuous one. 
2. The severity of OSD symptoms is positively 
correlated to the number of IOP-lowering medication 
used [53]. It’s important to underline that medical 
therapy has improved over the past decade through 
the introduction of more powerful topical drugs with 
long-lasting effects. These drugs make it possible to 
control IOP in many glaucoma patients with a once 
daily dose of a single agent. However, in some 
patients in whom IOP is not sufficiently controlled 
with monotherapy, adjunctive therapy is required. In 
such patients it is possible to use a fixed combination 
of glaucoma drugs, two IOP lowering agents 
combined in a single formulation. That’s why the 
introduction of combination therapies can be 
considered an important advancement in glaucoma 
therapy [54]. 
3. A complete and good clinical evaluation of OSD 
should be periodically performed. In the clinical 
evaluation of dry eye patients there is no actually 
established gold standard: several tests are used in the 
clinical practice which analyze patient’s symptoms, 
tear production, tear quality, ocular surface damage. 
All of these diagnostic test have low sensibility and 
little reproducibility, in particulary in patients with 
severe dry eye. Tear film hyperosmolarity is 
recognized as an important pathogenetic factor in dry 
eye syndrome, but its use is currently limited due to 
the complexity in its measurement [12, 55]. The same 
is true for confocal microscopy, a promising very 
good diagnostic tool with poor clinical practice yet 
[50, 55]. Arita R. et al. evaluated also how lid margin 
abnormality, superficial punctate keratopathy and 
meibum scores were higher in glaucoma patients 
under therapy, concluding how long-term use of 
antiglaucoma eye drops was associated with 
alterations in meibomian gland morphology and 
function [56]. 
 Considering these statements it becomes fundamental to 
evaluate periodically: 
− Schirmer test score 
− tear breakup time score with with fluorescein 1% 
− corneal staining with fluorescein 1% and a validate 
grading scale (i.e. National Eye Institute (N.E.I.) / 
Industry Workshop Scale; Oxford Grading Scale; 
SICCA ocular staining score) [57-59] 
− conjunctival staining preferably with lissamine green 
and a validate grading scale (i.e. National Eye 
Institute (N.E.I.) / Industry Workshop Scale; Oxford 
Grading Scale; SICCA ocular staining score) [57-59] 
− the quality of life with a validate questionnaire (i.e. 
OSDI questionnaires; Ocular Comfort Index (OCI)/ 
Ocular Symptom Scale (OSS) questionnaires) [60, 61] 
 A recent paper underlines the importance of the 
assessment of Quality of Life (QoL). [62]. This cross-
sectional study has been ruled with OSDI score and with 
Glaucoma Quality of Life-15 /GQL15 [62] and demonstrated 
that OSD is more common in patients with increasing 
glaucoma severity and is associated with poorer glaucoma-
related QoL and higher exposure to BAK. 
 It is fundamental to evaluate QoL with a validate method, 
i.e. the National Eye Institute Visual Function Questionnaire 
(NEI-VFQ) or the Ocular Surface Disease Index (OSDI). 
 Abnormal OSDI was found in a large number of 
glaucomatous and ocular hypertensive patients, even if large 
proportion of patients with severe OSDI has got normal or a 
mild to moderate alteration of clinical test. OSDI increases 
with the greater the number of glaucoma drugs prescribed. A 
large proportion of patients with severe OSDI had normal or 
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a mild to moderate alteration of clinical tests. Also 
psychological and environmental factors or the severity and 
awareness of the disease can influence OSDI [63]. 
 Li M et al. [64] underlined in a recent paper how vision-
related QoL in dry eye patients was impaired and was 
correlated with anxiety and depression, further implicating 
this condition as an important public health problem 
deserving increased attention and resources. 
CONCLUSION 
 Patients with topically treated glaucoma present OSD 
more often than a similar control group [65]. The presence of 
DED negatively influences the patient's QOL. The patients 
with glaucoma's ocular surface status should be evaluated 
regularly to ensure the timely detection and treatment of 
pathologic signs on the ocular surface. 
 The ocular surface injury not only causes dry eyes, red 
eye, eye itching, photophobia and other discomforts, but also 
increases the risk of failure of glaucoma surgery in patients 
[66]. 
 The commonly used preservative Benzalkonium Chloride 
(BAK) plays an important role in ocular surface damage and 
its side effects are dose- and time-dependent, particularly, in 
the combined medications. Good periodically clinical 
evaluation and prevention of ocular injury should be 
seriously taken into consideration in the anti-glaucoma 
medical treatment. Development of complex preparations, 
preservative-free and/or novel preservative preparations for 
glaucoma therapy could provide a promising approach in the 
prevention of ocular surface injury [52, 55, 66-68]. 
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